(Q38015162)

27 August 2017

title

Advances in the epidemiology, pathogenesis, and management of Cushing's syndrome complications (English)

1 reference

27 August 2017

0 references

1 reference

G Arnaldi

1

1 reference

27 August 2017

T Mancini

2

1 reference

27 August 2017

G Tirabassi

3

1 reference

27 August 2017

L Trementino

4

1 reference

27 August 2017

M Boscaro

5

1 reference

27 August 2017

publication date

1 April 2012

1 reference

Journal of Endocrinological Investigation

27 August 2017

published in

1 reference

27 August 2017

volume

35

1 reference

27 August 2017

issue

4

1 reference

27 August 2017

page(s)

434-448

1 reference

Diagnosis and complications of Cushing's syndrome: a consensus statement.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Treatment of adrenocorticotropin-dependent Cushing's syndrome: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Hypertension in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoid-dependent hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cardiovascular risk in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Circadian blood pressure profile in patients with Cushing's syndrome before and after treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Hypertension in Cushing’s Syndrome: From Pathogenesis to Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cushing's syndrome: all variants, detection, and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoid excess and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK: audit and meta-analysis of literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The metabolic syndrome and cardiovascular risk in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoids and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Left ventricular structural and functional characteristics in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cardiac dysfunction is reversed upon successful treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cardiovascular autonomic function in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cardiovascular risk factors and common carotid artery caliber and stiffness in patients with Cushing's disease during active disease and 1 year after disease remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Hypertrophic remodeling of subcutaneous small resistance arteries in patients with Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Impairment of flow-mediated vasodilatation of brachial artery in patients with Cushing's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Coagulopathy in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Hypercoagulable state in Cushing's syndrome: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Long-term follow-up results of transsphenoidal surgery for Cushing's disease in a single centre using strict criteria for remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Hyperhomocysteinemia in patients with Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Approach to the patient with possible Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Should we evaluate for cardiovascular disease in patients with Cushing's syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The pituitary-adrenal axis and body composition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Computed tomography assessment of fat distribution in male and female patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Classical endocrine diseases causing obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Expression profiling of 11beta-hydroxysteroid dehydrogenase type-1 and glucocorticoid-target genes in subcutaneous and omental human preadipocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Changes in adenosine 5'-monophosphate-activated protein kinase as a mechanism of visceral obesity in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Carbohydrate and lipid metabolism in endogenous hypercortisolism: shared features with metabolic syndrome X and NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Diagnosis and classification of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The European Registry on Cushing's syndrome: 2-year experience. Baseline demographic and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Pathophysiology of Diabetes Mellitus in Cushing’s Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Diabetes in Cushing syndrome: basic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Novel insights into glucocorticoid-mediated diabetogenic effects: towards expansion of therapeutic options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Adipose tissue as an endocrine organ

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Acute and 2-week exposure to prednisolone impair different aspects of beta-cell function in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Metabolic and cardiovascular outcomes in patients with Cushing's syndrome of different aetiologies during active disease and 1 year after remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Effect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Effect of pioglitazone on adrenocorticotropic hormone and cortisol secretion in Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Therapy in the early stage: incretins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Dipeptidyl peptidase-4 inhibitors and bone fractures: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The impact of glucocorticoid replacement regimens on metabolic outcome and comorbidity in hypopituitary patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Pathophysiology of dyslipidemia in Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Management of Dyslipidemia in Cushing’s Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoids and fatty acid metabolism in humans: fuelling fat redistribution in the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Insulin resistance, inflammation, and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Obesity and corticosteroids: 11beta-hydroxysteroid type 1 as a cause and therapeutic target in metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Human corticotropin releasing hormone test performance in the differential diagnosis between Cushing's disease and pseudo-Cushing state is enhanced by combined ACTH and cortisol analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Use of the desmopressin test in the differential diagnosis of pseudo-Cushing state from Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoid-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Mechanisms of glucocorticoid-induced myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Drug-induced and toxic myopathies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Experimental corticosteroid myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Clenbuterol antagonizes glucocorticoid-induced atrophy and fibre type transformation in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Respiratory muscle fibres: specialisation and plasticity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Myosin loss in denervated rat soleus muscle after dexamethasone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Molecular and cellular defects of skeletal muscle in an animal model of acute quadriplegic myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Steroid myopathy: some unresolved issues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Impact of physical training on the ultrastructure of midthigh muscle in normal subjects and in patients treated with glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Strenuous exercise-induced alterations of muscle fiber cross-sectional area and fiber-type distribution in steroid myopathy rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Skeletal diseases in Cushing's syndrome: osteoporosis versus arthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Perspectives on glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Skeletal involvement in adult patients with endogenous hypercortisolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Persistent increase of osteoprotegerin levels after cortisol normalization in patients with Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Nephrolithiasis in Cushing's disease: prevalence, etiopathogenesis, and modification after disease cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Growth hormone response to growth hormone-releasing hormone is reduced in adult asthmatic patients receiving long-term inhaled corticosteroid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Effects of Cushing disease on bone mineral density in a pediatric population

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Evaluation of bone mineral density of the peripheral skeleton in pre- and postmenopausal women with newly diagnosed endogenous Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have increased rate of vertebral fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Spine abnormalities and damage in patients cured from Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Recovery of bone mineral density after surgical cure, but not by ketoconazole treatment, in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Effectiveness of chronic treatment with alendronate in the osteoporosis of Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Prevention of glucocorticoid-induced bone loss in mice by inhibition of RANKL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid-induced osteoporosis: results of a randomized controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Growth hormone in glucocorticoid-induced osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Diagnostic categorization of psychiatric disturbance in Cushing's syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Psychiatric disorders associated with Cushing's syndrome. Epidemiology, pathophysiology and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Psychosomatic aspects of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Residual symptoms in depression an emerging therapeutic concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Altered amygdala and hippocampus function in adolescents with hypercortisolemia: a functional magnetic resonance imaging study of Cushing syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cognitive function and cerebral assessment in patients who have Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Persistent cognitive impairment following surgical treatment of Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Elevated cortisol levels in Cushing's disease are associated with cognitive decrements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Chronic glucocorticoid hypersecretion in Cushing's syndrome exacerbates cognitive aging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cushing's syndrome due to ectopic corticotropin secretion: twenty years' experience at the National Institutes of Health

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Reversible gonadotropin Deficiency in Male Cushing's Dusease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoid repression of the mouse gonadotropin-releasing hormone gene is mediated by promoter elements that are recognized by heteromeric complexes containing glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Glucocorticoid induces apoptosis in rat leydig cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Chronic corticosterone treatment impairs Leydig cell 11beta-hydroxysteroid dehydrogenase activity and LH-stimulated testosterone production

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Plasma Testosterone Profiles in Cushing's Syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Cushing's syndrome during pregnancy: personal experience and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Primary thyroid disorders in endogenous Cushing's syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Acute and chronic effects of high glucocorticoid levels on hypothalamic-pituitary-thyroid axis in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Paediatric Cushing's syndrome: epidemiology, investigation and therapeutic advances.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Final adult height and body mass index after cure of paediatric Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Endogenous and exogenous glucocorticoids decrease plasma ghrelin in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

The negative association between total ghrelin levels, body mass and insulin secretion is lost in hypercortisolemic patients with Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Comorbidity and cardiovascular risk factors in adult GH deficiency following treatment for Cushing's disease or non-functioning pituitary adenomas during childhood.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Clinical features of GH deficiency and effects of 3 years of GH replacement in adults with controlled Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Growth hormone deficiency and replacement in hypopituitary patients previously treated for acromegaly or Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Long-term impaired quality of life in Cushing's syndrome despite initial improvement after surgical remission.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Quality of life in patients with pituitary tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Quality of life in patients after long-term biochemical cure of Cushing's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Morbidity and mortality in Cushing's disease: an epidemiological approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Clinical relevance of cardiac structure and function abnormalities in patients with Cushing’s syndrome before and after cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FBF03345431

Steroid myopathy. Clinical, histologic and cytologic observations

21 January 2018

1 reference

12 December 2020

Spontaneous recovery of bone mass after cure of endogenous hypercortisolism

1 reference

12 December 2020

High prevalence of nodular thyroid disease in patients with Cushing's disease

1 reference

12 December 2020

Increased prevalence of thyroid autoimmunity in patients successfully treated for Cushing's disease

1 reference

12 December 2020

Losartan in Cushing's syndrome.

1 reference

12 December 2020

Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome

1 reference

12 December 2020

Bone mineral density and bone turnover before and after surgical cure of Cushing's syndrome.

1 reference

12 December 2020

Changes in coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery

1 reference

12 December 2020

Mortality and morbidity in Cushing's syndrome in New Zealand

1 reference

12 December 2020

The ovaries in Cushing's syndrome

1 reference

12 December 2020

Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome

1 reference

12 December 2020

The longitudinal course of psychopathology in Cushing's syndrome after correction of hypercortisolism.

1 reference

12 December 2020

Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow

1 reference

12 December 2020

Brain atrophy and cognitive deficits in Cushing's disease

1 reference

12 December 2020

Effect of Cushing's syndrome - Endogenous hypercortisolemia on cardiovascular autonomic functions

1 reference

12 December 2020

Children experience cognitive decline despite reversal of brain atrophy one year after resolution of Cushing syndrome

1 reference

12 December 2020

Acute administration of corticoids: a new and peculiar stimulus of growth hormone secretion in man

1 reference

12 December 2020

Glucocorticoid-induced muscle atrophy prevention by exercise in fast-twitch fibers

1 reference

12 December 2020

New insight into the hypercoagulability of Cushing's syndrome

1 reference

12 December 2020

Microsatellite (GT)(n) repeats and SNPs in the von Willebrand factor gene promoter do not influence circulating von Willebrand factor levels under normal conditions.

1 reference

12 December 2020

Estimation of body fat and lean tissue distribution by dual energy X-ray absorptiometry and abdominal body fat evaluation by computed tomography in Cushing's disease

1 reference

12 December 2020

Risk of new vertebral fractures in patients with adrenal incidentaloma with and without subclinical hypercortisolism: a multicenter longitudinal study

1 reference

12 December 2020

The nocturnal serum thyrotropin surge is abolished in patients with adrenocorticotropin (ACTH)-dependent or ACTH-independent Cushing's syndrome

1 reference

12 December 2020

Testicular activity in Cushing's disease

1 reference

12 December 2020

Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome

1 reference

12 December 2020

Blood pressure in children and adolescents with Cushing's syndrome before and after surgical care.

1 reference

12 December 2020

Patients with chronic glucocorticoid treatment develop changes in muscle glycogen metabolism

1 reference

12 December 2020

11 beta-Hydroxysteroid dehydrogenase activity in Cushing's syndrome: explaining the mineralocorticoid excess state of the ectopic adrenocorticotropin syndrome

1 reference

12 December 2020

The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state

1 reference

12 December 2020

Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure.

1 reference

12 December 2020

Menstrual abnormalities in women with Cushing's disease are correlated with hypercortisolemia rather than raised circulating androgen levels.

1 reference

12 December 2020

Persistent body fat mass and inflammatory marker increases after long-term cure of Cushing's syndrome

1 reference

12 December 2020

Contractile responses of rat fast-twitch and slow-twitch muscles to glucocorticoid treatment

1 reference

12 December 2020

LOCALISATION OF 11β-HYDROXYSTEROID DEHYDROGENASE—TISSUE SPECIFIC PROTECTOR OF THE MINERALOCORTICOID RECEPTOR

1 reference

12 December 2020

1 reference

12 December 2020

Left ventricular structural characteristics in Cushing's syndrome

1 reference

12 December 2020

Increased factor VIII associated activities in Cushing's syndrome: a probable hypercoagulable state.

1 reference

12 December 2020

Venous thrombo-embolism following inferior petrosal sinus sampling in Cushing's disease

1 reference

12 December 2020

[Prevalence of diabetes in acromegaly and Cushing syndrome]

1 reference

12 December 2020

Normal bone mineral density following cure of Cushing's syndrome

1 reference

12 December 2020

Cortisolemic indices predict severe infections in Cushing syndrome due to ectopic production of adrenocorticotropin

1 reference

12 December 2020

Microsatellite (GT)(n) is part of the von Willebrand factor (VWF) promoter region that influences the glucocorticoid-induced increase in VWF in Cushing's syndrome

1 reference

12 December 2020

Sleep architecture and sleep apnea in patients with Cushing's disease

1 reference

12 December 2020

Thyrotropin levels during hydrocortisone infusions that mimic fasting-induced cortisol elevations: a clinical research center study.

1 reference

12 December 2020

Dexamethasone suppresses sex-hormone binding globulin

1 reference

12 December 2020

Metabolic, Cardiovascular, and Cerebrovascular Outcomes in Growth Hormone-Deficient Subjects with Previous Cushing’s Disease or Non-Functioning Pituitary Adenoma

1 reference

12 December 2020

Drug-induced myopathies. An overview of the possible mechanisms.

1 reference

12 December 2020

Linear growth and final height after treatment for Cushing's disease in childhood

1 reference

12 December 2020

Trandolapril in Cushing's disease: short-term trandolapril treatment in patients with Cushing's disease and essential hypertension

1 reference

12 December 2020

Psychopathology in patients with endogenous Cushing's syndrome: ‘atypical’ or melancholic features

1 reference

12 December 2020

Quantitative ultrasound technology in evaluating bone status and osteoporosis in patients with Cushing's syndrome

1 reference

12 December 2020

Myopathies in the intensive care unit.

1 reference

12 December 2020

Psychiatric aspects of Cushing's syndrome

1 reference

12 December 2020

The Longitudinal Course of Psychopathology in Cushing’s Syndrome after Correction of Hypercortisolism

1 reference

12 December 2020

Identifiers

DOI

10.1007/BF03345431

1 reference

Dimensions Publication ID

27 August 2017

1027597420

0 references

1 reference